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Cytokine growth factor treatment of chronic wounds has met with mixed results. The chronic wound presents a
hostile environment to peptides such as growth factors. Cytokine growth factors have not been studied
extensively in acute wounds. However, incisional hernias are a major example of acute wound failure that
has not been solved by various mechanical approaches. A biological approach to acute wound failure by
use of cytokine growth factors may offer a new strategy. A rodent incisional hernia model was used. Seventy-
six rats underwent 3-cm midline celiotomies and were closed with fine, fast-absorbing sutures to induce
intentional acute wound failure. Group 1 received no other treatment. The midline fascia in Groups 2–10
was infiltrated with 100ml of vehicle alone or vehicle containing various test cytokine growth factors. Necropsy
was performed on postoperative day 28 and the wounds were examined for herniation. Incisional hernias
developed in 83 percent (13/16) of untreated incisional and 88 percent (7/8) and 83 percent (5/6) of the two
vehicle-treated incisions (PBS and carboxymethylcellulose). Hernia incidences were decreased by priming of
the fascial incision with transforming growth factor-b2 (12%, 1/8), basic fibroblast growth factor (25%, 2/8) and
interleukin-1b (50%, 3/6) (p < 0.05). Aqueous platelet-derived growth factor, becaplermin, insulin-like growth
factor, and granulocyte macrophage-colony stimulating factor did not significantly decrease the incidence
of acute wound failure (p > 0.05). A biological approach to acute wound failure as measured by incisional
hernia formation can be useful in reducing the incidence of this complication. Transforming growth factor-b2,
basic fibroblast growth factor, and interleukin 1b all eliminated or significantly reduced the development of
incisional hernias in the rat model. (WOUND REP REG 2004;12:38–43)
Exogenous application of cytokine growth factors has
been used to accelerate healing of chronic wounds.
Steed et al. first reported a successful clinical trial
using recombinant platelet-derived growth factor-BB
(PDGF-BB) to accelerate closure of diabetic foot
ulcers.1 Rees et al. used the same cytokine to shorten
the time of healing of pressure ulcers.2 Robson et al.
demonstrated that basic fibroblast growth factor
(bFGF) could also decrease the size of pressure ulcers
more effectively than a placebo control.3 Keratinocyte
growth factor-2 (KGF-2) appears to have been effective
in achieving closure in venous stasis ulcers, as has
transforming growth factor-b2 (TGF-b2).
4,5
Clinical success in treating chronic wounds
with exogenous cytokine growth factors has been
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disappointing. Despite numerous clinical trials, only
one growth factor has been approved by the US Food
and Drug Administration for clinical use. There are
several reasons for this situation.6 Chronic wounds
have a significant bacterial burden that is often not
controlled prior to treatment with growth factors.
Because bacteria degrade cytokine growth factors,
larger amounts are required to be effective.7 In addition
to the degradation of the cytokine growth factors,
bacteria produce proteases including matrix metallo-
proteinases (MMPs), both by themselves and as a pro-
duct of bacterial action on tissue cells.7 These
proteases and MMPS can degrade not only the growth
factor molecules but also the cytokine receptors.8,9
The acute wound, especially the surgical incision, is
a closedwoundwith a bacterial burden 100- to 1,000-fold
less than the chronic wound.10 Cytokine growth
factors have been shown to accelerate the rate of gain
of tensile strength in experimental incisions.11–13 This
occurs by shifting the wound healing trajectory curve
to the left.14 Not only can this be done at the time of
surgical incision, but as demonstrated by Smith et al., it
can be accomplished by initiating the inflammatory
phase of healing prior to tissue injury by injecting
cytokine growth factors in the area of the intended
incision.15 Combining this pretreatment with a cytokine
growth factor at the time of incision nearly doubled the
breaking strength of the acute wound.15
Acute wounds limited to the skin and subcuta-
neous tissue, although providing an experimental
model, usually heal clinically without significant mor-
bidity. Therefore, using a cytokine growth factor to
more rapidly gain tensile strength has no clinical utility.
However, deeper acute wounds involving the load-
bearing fascia and other layers of the abdominal wall can
present a major clinical problem. When acute wound
failure occurs in an incision into the abdominal cavity,
fascial dehiscence or an incisional hernia is the result.
Pre-operative studies with long-term follow up report
an 11–20 percent incidence of primary incisional hernia
following laparotomy.16 With approximately 4 million
abdominal operations performed annually in the United
States; this rate predicts 440,000–800,000 incisional her-
nias in this population.17 According to the National
Center for Health Statistics, approximately 200,000
operations are performed each year to repair ventral
incisional hernias in the United States alone.17 It is worri-
some that the frequency of this acute wound failure has
not diminished appreciably in the past 75 years.18
The problem of incisional hernias is intensified by
the high recurrence rate after repairs. Incisional hernia
recurrence rates range from 24 to 54 percent following
primary repair.16 A purely mechanical approach to
acute fascial wound failure has therefore not signifi-
cantly reduced the incidence of this important surgical
problem.19
An incisional hernia occurs as the result of a bio-
mechanical failure of the acute fascial wound early in
the healing trajectory when wound tensile strength is
very low or absent (days 0–30).20 It is during this time
when wound strength depends entirely on suture integ-
rity that recovering patients are returning to increased
levels of activity and placing increasing loads across
their acute wounds.19 Cytokine growth factors are an
important class of tissue repair-signaling peptides up-
regulated during the earliest phases of acute wound
healing.6,21 However, 5–7 days are required before
peak levels of fibroproliferative growth factors such
as TGF-b are reached in acute wounds.22 It was the
purpose of this study to determine whether providing
exogenous cytokine growth factors prior to the normal
physiologic peak can biologically accelerate strength-
ening of a fascial wound, thus preventing acute wound
failure and formation of an incisional hernia.
MATERIALS AND METHODS
Seventy-six Sprague-Dawley rats weighing 275–300 g
(Harlan Laboratories, Indianapolis, IN) were accli-
mated to laboratory conditions and fed standard rat
chow and water ad libitum. All procedures were per-
formed with the prior approval of the Ann Arbor Vet-
erans Affairs Medical Center Institutional Animal Care
and Use Committee (Ann Arbor, MI).
Animals were randomly assigned into one of ten
groups. Group 1 (n ¼ 16) underwent midline celiotomy
through the linea alba and received no further treat-
ment. In Group 2 (n ¼ 8) the vehicle control for the
aqueous cytokine growth factors was injected into the
midline fascia immediately prior to incision (phosphate
buffered saline solution [PBS]) and in Group 3 the
vehicle for becaplermin (0.1 percent caboxymethylcel-
lulose [CMC]) was injected into the midline fascia prior
to incision (n ¼ 6). In Groups 4–10 (n ¼ 46), the midline
fascia was treated with 1 mg of TGF-b2, 5 mg of aqueous
PDGF, 100 ml of becaplermin (Regranex), 1 mg of insulin-
like growth factor (IGF), 1mg of granulocytemacrophage-
colony stimulating factor (GM-CSF), or 1mg of
interleukin-1b (IL-1b) immediately prior to incision.
Incisional hernia model
Following intraperitoneal injection of ketamine (87mg/
kg) and xylozene (13mg/kg) for anesthesia, ventral
abdominal hair was shaved with electric clippers and
the field was prepped with alcohol solution. A 6-cm
full-thickness dermal incision was placed 2 cm lateral
to the ventral midline and a rectangular skin flap was
subsequently fashioned and raised through the avascu-
lar prefascial plane, exposing the linea alba.19 A 3-cm
isolated celiotomy incision was then placed through
the fascia of the midline linea alba, thereby separating
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the skin incision from the underlying fascial wound.
The design of this ventral abdominal wall dermal flap
model allows acute fascial healing to occur isolated
from the overlying dermal wound.23 The fascial incision
was then closed with a single 5–0 plain catgut suture
placed across the mid-wound with 0.5 cm bites.
Previous experience with this model predicts an 80 per-
cent incidence of fascial incisional hernias after 28
days.19,24 The skin flap was then replaced and the der-
mal incisions were closed with a running 4–0 polyga-
lactone suture. Following 30minutes of recovery under
heat lamps, the rats were returned to individual cages.
Standard chow and water were again provided ad libitum.
Exogenous cytokine growth factor treatment
In Group 2, 100 ml of vehicle (PBS) was injected evenly
into the linea alba using a tuberculin syringe immedi-
ately prior to fascial incision (‘‘priming’’)15 In Group
3, 100 ml of CMC vehicle was injected for the priming
becaplermin control. In Groups 4–10, 100 ml of the test
cytokine was used as the priming solution. A 3.0-cm
midline celiotomy was then performed and the fascial
incision was immediately closed with a single 5–0 plain
catgut suture placed across the mid wound, as
described above.
Tissue processing
All rats were killed on postoperative day 28 by intra-
peritoneal pentobarbitol overdose (100mg/kg) or CO2
asphyxiation. The entire abdominal wall was then
excised and the skin separated from the musculofascial
layer. The peritoneal and subcutaneous surfaces of
each abdominal wall were then carefully inspected for
the presence of herniated abdominal contents. A min-
imum of 2mm fascial separation was required for a
wound to be scored as containing an incisional her-
nia.19,24 Sagittal fascial wound and/or hernia sections
were then cut and immediately fixed in 10 percent
buffered formalin. The fixed sections were embedded
in paraffin, sectioned, and stained with hematoxylin
and eosin (H&E).
Statistical analysis
Data was analyzed using Sigma Stat software (Jandel
Scientific, Corte Madera, CA). The Chi-squared test was
used to determine differences in the incidence of inci-
sional hernias. p-values of <0.05 were considered
significant.
RESULTS
Incisional hernias developed in 83 percent (13/16) of
the untreated fascial incisions and in 88 percent (7/8)
and 83 percent (5/6) of the two vehicle control groups
(Groups 2 and 3) after 28 days. (Table 1) TGF-b2 (12
percent, 1/8), bFGF (25 percent, 2/8) and IL-1b (50
percent, 3/6) all significantly lowered the incidence of
incisional hernia formation (p<0.05). The remaining
cytokine growth factor-treated incisions revealed no
changes in the incidence of acute wound failure (aque-
ous PDGF-BB, becaplermin, IGF and GM-CSF
[Table 1]). Accelerated fascial repair was associated
with abundant collagen and extracellular matrix
deposition and neovascularization (Figure 1).
There were two deaths during the study period,
both due to acute herniation and or strangulation. One
acute herniation occurred in each of the becaplermin
and IGF groups.
DISCUSSION
Acute wound failure remains a frequent source of mor-
bidity and mortality following injury. Abdominal wall
Table 1. Incidence of ventral incisional hernia formation
with or without cytokine growth factor priming of the abdom-
inal wall prior to wound closure
Treatment modality N Number of incisional hernias (%)
Untreated control 16 13 (83)
PBS control 8 7 (88)
CMC control 6 5 (83)
PDGF priming 6 6 (100)
Becaplermin priming 6 6 (100)
GM-CSF priming 6 6 (100)
IGF-1 priming 6 6 (100)
TGF- b 8 1 (12) *
bFGF 8 2 (25) *
IL-1 6 3 (50)†
*Significantly different compared to control (p< 0.05).





FIGURE 1. Representative histological specimen of a 28-day
midline fascial incision primed with 1mg of TGF-b that did not
herniate. There is enhanced fibroplasia and abundant
neovascularization. (Trichrome staining, original magnification
· 200)
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fascial dehiscence and incisional herniation are com-
mon. Prospective, well-controlled studies find that
incisional hernias complicate 11 percent of all abdom-
inal wall closures following celiotomy.20 In one of three
abdominal wall closures, the fascial layer of the wound
fails to heal in patients operated upon for aortic aneu-
rysm disease, during periods of hemodynamic instability
or in those with gross contamination of the deep
wound space, especially in malnourished patients.18
The result is 200,000 incisional hernia repairs that are
performed each year in the United States at a financial
cost of nearly 2.5 billion dollars.17 With nearly four
million abdominal and pelvic operations performed
each year in the United States, it is estimated that
another 200,000 incisional hernias may be going unrec-
ognized or untreated.
Incisional hernias occur as the result of the com-
bined bio-mechanical failure of an acute fascial wound
early in the healing trajectory. This is not surprising
when considering the clinically relevant impediments to
acute tissue repair together with the normal function of
the abdominal wall to support increasing loads during
the postoperative recovery period.17,24 Most studies now
support the concept that acute fascial separation occurs
early in the postoperative period, leading to the delayed
clinical development of abdominal wall incisional her-
nias. Mechanical failure occurs early in the trajectory of
acute wound healing at a time when wound tensile
strength is very low or absent (postoperative days 0–
30). It is during the earliest period of acute wound healing
that the wound depends entirely on suture integrity to
maintain abdominal wall closure. Simultaneously, most
patients are recovering from their procedures and return-
ing to increased levels of activity and placing increasing
loads across the acute wound during its weakest phase.
The most frequently identified clinical risk factors for
primary fascial wound failure and primary incisional her-
nia formation include a suboptimal closure technique,
deep wound infections, malnutrition, peri-operative
hypotension, steroid use, and aortic aneurysm disease.18
Abnormal progression of the acute wound healing
trajectory impairs the recovery of wound tensile
strength.14 A biological intervention at the host wound
level designed to optimize fascial healing may prevent
and/or treat incisional hernias. To date, systematic stud-
ies have been difficult due to the lack of a reprodu-
cible animal model of incisional hernias. A model of
incisional hernia formation was therefore designed
with the intentional early failure of the fascial suture.19
In this rodent model, there is progressive midline
abdominal wall wound healing failure that reliably
results in acute fascial separation early in the post-
operative period. The incisional hernias that develop
have a well-defined hernia ring, hernia sacs, and visc-
eral adhesions, all characteristic of the incisional her-
nias that clinically develop in humans.
The cellular and molecular pathways of acute tis-
sue repair are easily conceptualized as a sequence of
three time-limited phases: hemostasis/inflammation
(lag), proliferative, and remodeling (Figure 2). The
‘‘lag’’ designation attributed to the initial inflammatory
phase of acute wound healing represents the time
required for recruiting the many cellular elements acti-
vated during early repair and the total absence of
mechanical strength that exists for several days to
weeks. Fundamental among the cellular and biochem-
ical events occurring during each of these phases of
acute tissue repair are release or activation of molecu-
lar cytokine messengers that regulate cell–cell and
cell–matrix interactions during wound repair.21
The improved understanding of the cellular and
molecular pathways activated during acute tissue
repair now allows the application of biological
approaches to the problem of incisional hernia forma-
tion. This study showed that augmenting biological
growth factor levels during the lag period of acute
fascial repair prevents the formation of incisional her-
nias. Endogenous tissue growth factors are an import-
ant class of repair-signaling peptides up-regulated
during the inflammatory phase of acute wound healing.
Growth factors recruit and activate the cellular and
molecular components necessary for the fibroprolifera-
tive burst that characterizes the lag phase of acute
wound healing. Acute wound therapy with proliferative
growth factors was shown to accelerate the appear-
ance of fibroblasts and collagen into the wound,
thereby shortening the natural lag-phase for gain
in injured tissue tensile strength. Several reports




























FIGURE 2. Growth factor priming of acute wound sites
preactivates the cellular and molecular components of
acute tissue repair prior to tissue injury. The surgical and
pharmacological strategy is to shorten or eliminate the lag-
phase for tissue repair. This is especially important for load-
bearing structures like the abdominal wall where a temporal
balance must be struck between increased wound loads and
the assembly of the tissue repair components required to
withstand that mechanical force.
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angiogenesis-stimulating ability of bFGF in the dermis.25
The current study was designed to determine whether
other cytokine growth factors more efficiently acceler-
ate fascial incisional wound healing, thereby reducing
the incidence of incisional hernia formation.
Biologically augmenting fascial repair following
celiotomy lowered the incidence of fascial separation
in the rat model of intentional abdominal wall wound
failure. bFGF treatment induced pronounced angiogen-
esis, earlier fibroplasia, and enhanced collagen produc-
tion within the acute fascial wound. In vivo, bFGF
appears in high initial peak concentration in the early
acute wound fluid (within 48 hours), and then tapers off
to baseline levels within a few days.26 This pharmaco-
kinetic pattern is characteristic of IGF, epidermal
growth factor, PDGF-AB, and TGF-b1.27 The early-
response growth factors are known to recruit the cel-
lular and molecular events necessary for the transition
to the fibroproliferative stage. Specifically, bFGF sti-
mulates endothelial cell proliferation and induces the
production of proteases, required for neovessel pene-
tration through the extracellular matrix.27 Basic FGF
also has modest fibroproliferative-stimulating proper-
ties. These biological functions theoretically make
bFGF the ideal growth factor for penetrating the organ-
ized mature dense scar that characterizes incisional
hernia rings with proteases and stimulating neovascu-
larization to support primary apposition of the fascial
edges. Several other advantageous clinical applications
for bFGF have been shown in experimental animal
models of acute wound healing in tissues with relatively
poor blood supply. Incorporation of tracheal autografts,
devascularized sternal wound healing, fractured bone
healing, and tendon repair have all been shown to have
enhanced wound healing with the application of bFGF
to the acute wound.28–30 bFGF also improves healing
parameters in patients with dysfunctional wound repair
such as those with diabetes mellitus.31
Growth factor delivery remains a difficult problem
in models of acute wound healing. Previously described
techniques all have shortcomings. Applying the growth
factors as an aqueous preparation to an open incision
makes containment within the wound difficult and
equal distribution throughout the wound nearly impos-
sible. CMC suspensions improve the handling and deliv-
ery of growth factors for open wound models, but are
cumbersome and unreliable for closed primary
wounds. Fibrin-based carriers can also improve growth
factor delivery but may act as mechanical barriers to
incision healing at specific concentrations. We pre-
viously reported an aqueous TGF-b2 preparation
injected into the prospective wound site prior to inci-
sion using a small-diameter needle system.19 This
‘‘priming’’ of the tissue prior to injury allows ease of
handling but had the shortcomings of a single-dose
delivery and difficult application in the treatment of
developed incisional hernias with separated fascial
edges.
While predominantly fibroproliferative and angio-
genic growth factors like TGF-b and bFGF lowered the
incidence of herniation, aqueous and CMC-bound
PDGF may have actually impaired fascial acute fascial
healing, possibly due to an abnormally prolonged or
intense inflammatory phase. This may also be the rea-
son GM-CSF had no effect or even an inhibitory effect
on fascial repair. The observation that IL-1 trended
toward a significant reduction in the incidence of inci-
sional herniation was a surprise. Others have reported
the property of IL-1 to stimulate apoptotic fibroblasts
derived from chronic dermal wounds back into a pro-
liferative cell cycle.32 The same effect may have been
observed in this study of acute wound failure. We pre-
viously showed that acute fascial wound fibroblasts
undergo cell-cycle arrest and perhaps apoptosis soon
after the loss of mechanical signaling when fascial
separation occurs.33
Clinically, a combined biomechanical approach
similar to the one reported here may be applied espe-
cially in cases where there is a high risk for acute
fascial wound failure. These would include, for example,
recurrent incisional herniorrhaphy, acute wounds in
patients older than 60, those closed during hemody-
namic instability or in the setting of abdominal sepsis,
severely malnourished patients, and those wounds
associated with abdominal aortic aneurysm or morbid
obesity surgery. Acute wound therapy with prolifera-
tive growth factors offers a promising new strategy
for reducing the incidence of this common surgical
complication.
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